Heme catabolism by tumor-associated macrophages controls metastasis formation.

Animals Antineoplastic Agents, Immunological / pharmacology Biomarkers, Tumor / antagonists & inhibitors Cell Line, Tumor / transplantation Chemotherapy, Adjuvant / methods Disease Models, Animal Epithelial-Mesenchymal Transition / immunology Female Heme / metabolism Heme Oxygenase-1 / antagonists & inhibitors Humans Kaplan-Meier Estimate Lung Neoplasms / immunology Male Melanoma / immunology Membrane Proteins / antagonists & inhibitors Mice Mice, Transgenic Myeloid Progenitor Cells / immunology Skin Neoplasms / immunology Tumor Escape / drug effects Tumor Microenvironment / drug effects Tumor-Associated Macrophages / immunology

Journal

Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354

Informations de publication

Date de publication:
05 2021
Historique:
received: 27 01 2020
accepted: 19 03 2021
pubmed: 28 4 2021
medline: 22 7 2021
entrez: 27 4 2021
Statut: ppublish

Résumé

Although the pathological significance of tumor-associated macrophage (TAM) heterogeneity is still poorly understood, TAM reprogramming is viewed as a promising anticancer therapy. Here we show that a distinct subset of TAMs (F4/80

Identifiants

DOI: 10.1038/s41590-021-00921-5 PMID: 33903766
pubmed: 33903766
doi: 10.1038/s41590-021-00921-5
pii: 10.1038/s41590-021-00921-5
doi:

Substances chimiques

Antineoplastic Agents, Immunological 0
Biomarkers, Tumor 0
Membrane Proteins 0
Heme 42VZT0U6YR
HMOX1 protein, human EC 1.14.14.18
Heme Oxygenase-1 EC 1.14.14.18
Hmox1 protein, mouse EC 1.14.14.18

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

595-606

Références

Ueha, S., Shand, F. H. & Matsushima, K. Myeloid cell population dynamics in healthy and tumor-bearing mice. Int. Immunopharmacol. 11, 783–788 (2011).
pubmed: 21406269 doi: 10.1016/j.intimp.2011.03.003
Yang, M., McKay, D., Pollard, J. W. & Lewis, C. E. Diverse functions of macrophages in different tumor microenvironments. Cancer Res. 78, 5492–5503 (2018).
pubmed: 30206177 pmcid: 6171744 doi: 10.1158/0008-5472.CAN-18-1367
Gordon, S. & Pluddemann, A. The mononuclear phagocytic system. Generation of diversity. Front. Immunol. 10, 1893 (2019).
pubmed: 31447860 pmcid: 6696592 doi: 10.3389/fimmu.2019.01893
Strauss, L. et al. RORC1 regulates tumor-promoting ‘emergency’ granulo-monocytopoiesis. Cancer Cell 28, 253–269 (2015).
pubmed: 26267538 doi: 10.1016/j.ccell.2015.07.006
Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008).
pubmed: 18650914 doi: 10.1038/nature07205
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399–416 (2017).
pubmed: 28117416 pmcid: 5480600 doi: 10.1038/nrclinonc.2016.217
Sica, A., Guarneri, V. & Gennari, A. Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression. Cell Stress 3, 284–294 (2019).
pubmed: 31535085 pmcid: 6732213 doi: 10.15698/cst2019.09.197
Mehla, K. & Singh, P. K. Metabolic regulation of macrophage polarization in cancer. Trends Cancer 5, 822–834 (2019).
pubmed: 31813459 pmcid: 7187927 doi: 10.1016/j.trecan.2019.10.007
Blagih, J. & Jones, R. G. Polarizing macrophages through reprogramming of glucose metabolism. Cell Metab. 15, 793–795 (2012).
pubmed: 22682218 doi: 10.1016/j.cmet.2012.05.008
Wang, D., Paz-Priel, I. & Friedman, A. D. NF-κB p50 regulates C/EBPα expression and inflammatory cytokine-induced neutrophil production. J. Immunol. 182, 5757–5762 (2009).
pubmed: 19380823 doi: 10.4049/jimmunol.0803861
Porta, C. et al. Protumor steering of cancer inflammation by p50 NF-κB enhances colorectal cancer progression. Cancer Immunol. Res. 6, 578–593 (2018).
pubmed: 29588321 doi: 10.1158/2326-6066.CIR-17-0036
Ziegler-Heitbrock, L. The p50-homodimer mechanism in tolerance to LPS. J. Endotoxin Res. 7, 219–222 (2001).
pubmed: 11581573 doi: 10.1177/09680519010070030401
Porta, C. et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κB. Proc. Natl Acad. Sci. USA 106, 14978–14983 (2009).
pubmed: 19706447 doi: 10.1073/pnas.0809784106 pmcid: 2736429
Gozzelino, R., Jeney, V. & Soares, M. P. Mechanisms of cell protection by heme oxygenase-1. Annu. Rev. Pharmacol. Toxicol. 50, 323–354 (2010).
pubmed: 20055707 doi: 10.1146/annurev.pharmtox.010909.105600
Sica, A. et al. Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes. J. Exp. Med. 185, 969–974 (1997).
pubmed: 9120403 pmcid: 2196159 doi: 10.1084/jem.185.5.969
Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A. & Lambris, J. D. Complement in cancer: untangling an intricate relationship. Nat. Rev. Immunol. 18, 5–18 (2018).
pubmed: 28920587 doi: 10.1038/nri.2017.97
Schraufstatter, I. U., Discipio, R. G., Zhao, M. & Khaldoyanidi, S. K. C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J. Immunol. 182, 3827–3836 (2009).
pubmed: 19265162 doi: 10.4049/jimmunol.0803055
De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211–226 (2005).
pubmed: 16169466 doi: 10.1016/j.ccr.2005.08.002
Jenkins, S. J. & Hume, D. A. Homeostasis in the mononuclear phagocyte system. Trends Immunol. 35, 358–367 (2014).
pubmed: 25047416 doi: 10.1016/j.it.2014.06.006
Saccani, A. et al. p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 66, 11432–11440 (2006).
pubmed: 17145890 doi: 10.1158/0008-5472.CAN-06-1867
Vadrevu, S. K. et al. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 74, 3454–3465 (2014).
pubmed: 24786787 doi: 10.1158/0008-5472.CAN-14-0157
Markiewski, M. M. et al. Modulation of the antitumor immune response by complement. Nat. Immunol. 9, 1225–1235 (2008).
pubmed: 18820683 pmcid: 2678913 doi: 10.1038/ni.1655
Cassetta, L. et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell 35, 588–602 (2019).
pubmed: 30930117 pmcid: 6472943 doi: 10.1016/j.ccell.2019.02.009
Gozzelino, R. & Soares, M. P. Coupling heme and iron metabolism via ferritin H chain. Antioxid. Redox Signal. 20, 1754–1769 (2014).
pubmed: 24124891 pmcid: 3961798 doi: 10.1089/ars.2013.5666
Otterbein, L. E. et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat. Med. 6, 422–428 (2000).
pubmed: 10742149 doi: 10.1038/74680
Nitti, M. et al. HO-1 induction in cancer progression: a matter of cell adaptation. Antioxididants (Basel) 6, 29 (2017).
Weis, N., Weigert, A., von Knethen, A. & Brune, B. Heme oxygenase-1 contributes to an alternative macrophage activation profile induced by apoptotic cell supernatants. Mol. Biol. Cell 20, 1280–1288 (2009).
pubmed: 19129475 pmcid: 2649271 doi: 10.1091/mbc.e08-10-1005
Ponka, P. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 89, 1–25 (1997).
pubmed: 8978272 doi: 10.1182/blood.V89.1.1
Park, J. Y. et al. Polarized CD163
pubmed: 26508473 doi: 10.1016/j.clinre.2015.09.005
Brouard, S. et al. Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-κB to protect endothelial cells from tumor necrosis factor-α-mediated apoptosis. J. Biol. Chem. 277, 17950–17961 (2002).
pubmed: 11880364 doi: 10.1074/jbc.M108317200
Zhou, C. et al. The heme oxygenase-1 inhibitor ZnPPIX induces non-canonical, Beclin 1-independent, autophagy through p38 MAPK pathway. Acta Biochim. Biophys. Sin. (Shanghai) 44, 815–822 (2012).
doi: 10.1093/abbs/gms064
Sun, J. et al. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J. 21, 5216–5224 (2002).
pubmed: 12356737 pmcid: 129038 doi: 10.1093/emboj/cdf516
Ren, D. et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl Acad. Sci. USA 108, 1433–1438 (2011).
pubmed: 21205897 doi: 10.1073/pnas.1014275108 pmcid: 3029730
Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).
pubmed: 22437938 pmcid: 3587148 doi: 10.1038/nri3175
McArdle, A. J. et al. Determinants of carboxyhemoglobin levels and relationship with sepsis in a retrospective cohort of preterm neonates. PLoS ONE 11, e0161784 (2016).
pubmed: 27552216 pmcid: 4995038 doi: 10.1371/journal.pone.0161784
Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787–795 (2012).
pubmed: 22378047 pmcid: 3287223 doi: 10.1172/JCI59643
Ribas, A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366, 2517–2519 (2012).
pubmed: 22658126 doi: 10.1056/NEJMe1205943
Wu, W. C. et al. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. Proc. Natl Acad. Sci. USA 111, 4221–4226 (2014).
pubmed: 24591638 doi: 10.1073/pnas.1320753111 pmcid: 3964061
Hoeffel, G. & Ginhoux, F. Fetal monocytes and the origins of tissue-resident macrophages. Cell. Immunol. 330, 5–15 (2018).
pubmed: 29475558 doi: 10.1016/j.cellimm.2018.01.001
Korolnek, T. & Hamza, I. Macrophages and iron trafficking at the birth and death of red cells. Blood 125, 2893–2897 (2015).
pubmed: 25778532 pmcid: 4424413 doi: 10.1182/blood-2014-12-567776
Soares, M. P. & Bach, F. H. Heme oxygenase-1: from biology to therapeutic potential. Trends Mol. Med. 15, 50–58 (2009).
pubmed: 19162549 doi: 10.1016/j.molmed.2008.12.004
Nemeth, Z. et al. Heme oxygenase-1 in macrophages controls prostate cancer progression. Oncotarget 6, 33675–33688 (2015).
pubmed: 26418896 pmcid: 4741794 doi: 10.18632/oncotarget.5284
Chan, K., Lu, R., Chang, J. C. & Kan, Y. W. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc. Natl Acad. Sci. USA 93, 13943–13948 (1996).
pubmed: 8943040 doi: 10.1073/pnas.93.24.13943 pmcid: 19474
Carminati, L. et al. Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. Carcinogenesis 40, 303–312 (2019).
pubmed: 30544170 doi: 10.1093/carcin/bgy177
Biswas, S. K. et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation). Blood 107, 2112–2122 (2006).
pubmed: 16269622 doi: 10.1182/blood-2005-01-0428
Sensi, M. et al. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8
pubmed: 15695408 doi: 10.1158/0008-5472.632.65.2
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 25605792 pmcid: 4402510 doi: 10.1093/nar/gkv007
Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat. Protoc. 4, 1184–1191 (2009).
pubmed: 19617889 pmcid: 3159387 doi: 10.1038/nprot.2009.97
Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284–287 (2012).
pubmed: 22455463 pmcid: 3339379 doi: 10.1089/omi.2011.0118
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 doi: 10.1073/pnas.0506580102 pmcid: 1239896
Li, T. et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77, e108–e110 (2017).
pubmed: 29092952 pmcid: 6042652 doi: 10.1158/0008-5472.CAN-17-0307
Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550–1558 (2018).
pubmed: 30127393 pmcid: 6487502 doi: 10.1038/s41591-018-0136-1

Auteurs

Francesca Maria Consonni (FM)

Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
Department of Pharmaceutical Sciences, University of Piemonte Orientale 'A. Avogadro', Novara, Italy.

Augusto Bleve (A)

Department of Pharmaceutical Sciences, University of Piemonte Orientale 'A. Avogadro', Novara, Italy.

Maria Grazia Totaro (MG)

Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.

Mariangela Storto (M)

Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.

Paolo Kunderfranco (P)

Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
ORCID: 0000-0003-3636-3391

Alberto Termanini (A)

Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
ORCID: 0000-0002-9697-906X

Fabio Pasqualini (F)

Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.

Chiara Alì (C)

Department of Pharmaceutical Sciences, University of Piemonte Orientale 'A. Avogadro', Novara, Italy.

Chiara Pandolfo (C)

Department of Pharmaceutical Sciences, University of Piemonte Orientale 'A. Avogadro', Novara, Italy.

Francesco Sgambelluri (F)

Department of Research, Human Tumors Immunobiology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.

Giulia Grazia (G)

Department of Research, Human Tumors Immunobiology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.

Mario Santinami (M)

Department of Surgery, Melanoma and Sarcoma Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.

Andrea Maurichi (A)

Department of Surgery, Melanoma and Sarcoma Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.

Massimo Milione (M)

First Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Marco Erreni (M)

Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
ORCID: 0000-0002-1922-0818

Andrea Doni (A)

Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.

Marco Fabbri (M)

European Commission, Joint Research Centre (JRC), Ispra, Italy.
ORCID: 0000-0002-7056-4691

Laura Gribaldo (L)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Eliana Rulli (E)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Miguel Parreira Soares (MP)

Instituto Gulbenkian de Ciência, Oeiras, Portugal.
ORCID: 0000-0002-9314-4833

Valter Torri (V)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Roberta Mortarini (R)

Department of Research, Human Tumors Immunobiology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.

Andrea Anichini (A)

Department of Research, Human Tumors Immunobiology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
ORCID: 0000-0001-5096-5538

Antonio Sica (A)

Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy. antonio.sica@uniupo.it.
Department of Pharmaceutical Sciences, University of Piemonte Orientale 'A. Avogadro', Novara, Italy. antonio.sica@uniupo.it.
ORCID: 0000-0002-8342-7442

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Heme catabolism by tumor-associated...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Heme catabolism by tumor-associated...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Heme catabolism by tumor-associated...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Heme catabolism by tumor-associated...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Traitement médicamenteux adjuvant › Heme catabolism by tumor-associated...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Heme catabolism by tumor-associated...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transdifférenciation cellulaire › Transition épithélio-mésenchymateuse › Heme catabolism by tumor-associated...
questionsmedicales.fr › Facteurs biologiques › Pigments biologiques › Porphyrines › Métalloporphyrines › Hème › Heme catabolism by tumor-associated...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Oxygénases › Mixed function oxygenases › Heme oxygenase (decyclizing) › Heme oxygenase-1 › Heme catabolism by tumor-associated...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Heme catabolism by tumor-associated...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Estimation de Kaplan-Meier › Heme catabolism by tumor-associated...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Heme catabolism by tumor-associated...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Naevus et mélanomes › Mélanome › Heme catabolism by tumor-associated...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Heme catabolism by tumor-associated...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Heme catabolism by tumor-associated...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Heme catabolism by tumor-associated...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système hématopoïétique › Cellules de la moelle osseuse › Cellules souches hématopoïétiques › Progéniteurs myéloïdes › Heme catabolism by tumor-associated...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Tumeurs cutanées › Heme catabolism by tumor-associated...
questionsmedicales.fr › Phénomènes du système immunitaire › Échappement de la tumeur à la surveillance immunitaire › Heme catabolism by tumor-associated...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Heme catabolism by tumor-associated...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Macrophages › Macrophages associés aux tumeurs › Heme catabolism by tumor-associated...